Skip to main content
NCBI home page
Cancer Science logoLink to Cancer Science
. 2014 Sep 23;105(10):1229–1235. doi: 10.1111/cas.12502

PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer

Kayoko Waki 1, Teppei Yamada 2, Koichi Yoshiyama 3, Yasuhiro Terazaki 3, Shinjiro Sakamoto 2, Satoko Matsueda 1,2, Nobukazu Komatsu 4, Shunichi Sugawara 5, Shinzo Takamori 3, Kyogo Itoh 2, Akira Yamada 1,✉
PMCID: PMC4462362  PMID: 25117757

Abstract

PD-1 expression in peripheral blood T-cells has been reported in several kinds of cancers, including lung cancer. However, the relationship between PD-1 expression in peripheral blood T-cells and prognosis after treatment with a cancer vaccine has not been reported. To elucidate this relationship, we analyzed PD-1 expression in the peripheral blood T-cells of patients with non-small cell lung cancer. The blood samples used in this study were obtained from patients enrolled in phase II clinical trials of a personalized peptide vaccine. Seventy-eight samples obtained before and after a single vaccination cycle (consisting of six or eight doses) were subjected to the analysis. PD-1 was expressed on lymphocytes in the majority of samples. The relative contents of PD1+CD4+ T-cells against total lymphocytes before and after the vaccination cycle correlated with overall survival (OS) with a high degree of statistical significance (P < 0.0001 and P = 0.0014). A decrease in PD-1+CD8+ T-cells after one cycle of vaccination also correlated with longer OS (P = 0.032). The IgG response to the non-vaccinated peptides suggested that the epitope spreading seemed to occur more frequently in high-PD-1+CD4+ T-cell groups. Enrichment of CD45RA−CCR7− effector-memory phenotype cells in PD-1+ T-cells in PBMCs was also shown. These results suggest that PD-1 expression on the peripheral blood T-cell subsets can become a new prognostic marker in non-small cell lung cancer patients treated with personalized peptide vaccination.

Keywords: Biomarker, lung cancer, PD-1, peptide vaccine, prognosis

Lung cancer is the most common cancer in the world; annually 1.8 million new cases are diagnosed and 1.6 million people die of the disease.1 Approximately 80% of lung cancers are non-small cell lung cancers (NSCLCs).2 Surgery is the standard treatment in the early stages of NSCLC. However, more than 65% of patients with NSCLC are in advanced stages with locally advanced or metastatic disease.3 Although recent progress with molecular targeted agents, including tyrosine kinase inhibitors of epidermal cell growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), as well as progress in the development of antibodies against vascular endothelial cell growth factor (VEGFR), improved the prognosis of NSCLC patients in advanced stages,4,5 new treatment modalities need to be developed. Cancer vaccine therapies are among the promising new therapeutic modalities for NSCLC. We have developed a personalized peptide vaccine (PPV), in which appropriate vaccine peptides are selected from a panel of candidate peptides on the basis of each patient's HLA-A types and pre-existing anti-cancer immunity.6 Currently, there are 31 CTL-epitope peptide candidates derived from a variety of tumor-associated antigens; these include12 peptides for HLA-A2 patients, nine peptides for patients with an HLA-A3 super type (A3, A11, A31, or A33), 14 peptides for HLA-A24 patients, and four peptides for HLA-A26 patients.6,7 A maximum of four peptides, which were selected based on patient's HLA types and pre-existing immunity, were subcutaneously injected with ISA51VG weekly or bi-weekly. Clinical studies have shown the safety and potential immunological efficacy of these peptides in small cell and non-small cell lung cancers.8,9

Anti-tumor immunity is regulated by several immune check point molecules. Programmed cell death1 (PD-1) is one of the immune check point molecules expressed on both activated and exhausted T-cells.10 PD-L1, the PD-1 ligand, is expressed on tumor cells and PD-1/PD-L1 interaction provide negative signal for antigen-induced T-cell activation.11 Therefore, T-cell inactivation induced by PD-1/PD-L1 is thought to be a mechanism underlying immunosuppression at the tumor site.11 Several reports have examined PD-1 expression on tumor-infiltrating T-cells, and its correlation with prognosis has been discussed.12–19 However, PD-1 expression on the peripheral blood T-cells of cancer patients, particularly in those with lung cancer, has not been sufficiently studied.20–22 In this paper, we analyzed PD-1 expression and other immune check point molecules on peripheral blood T-cells of NSCLC patients and found some correlation with prognosis.

Materials and Methods

Clinical samples

The peripheral blood samples used in this study were obtained from patients enrolled in phase II clinical trials of PPV for advanced NSCLC. The study protocols were approved by the Kurume University Ethics Committee and were registered with the UMIN Clinical Trial Registry, UMIN 1839 and UMIN 2984. The entry criteria and precise vaccination protocols were reported previously. One vaccination cycle consisted of six or eight doses of peptide vaccination. The patient's blood samples were taken before and after one cycle and stored until use.

Flow cytometric analysis

Peripheral blood mononuclear cells (1 × 105) were suspended in PBS containing 20% human AB serum and incubated for 30 min on ice with appropriate dilution of antibodies. The antibodies used in this study were: anti-CD4-FITC (clone RPA-T4), anti-CD8-PerCP-Cy5.5 (clone RPA-T8), anti-CD279 (PD-1)-APC (clone MIH4), anti-CD152 (CTLA-4)-APC, and anti-CD137 (4-1BB)-APC from BD Biosciences (Franklin Lakes, NJ, USA), anti-CD197 (CCR7)-PerCP-Cy5.5 (clone G043H7), anti-CCR7-Alexa Fluor 488 (clone G043H7), and anti-CD45RA-PE (clone HI100) from BioLegend (San Diego, CA, USA). For the negative controls, APC mouse IgG1(κ) (clone MOPC-21; BD Biosciences) and PE mouse IgG2b (κ) (clone MPC-11; BioLegend) were used. The stained cells were analyzed on BD FACS Canto II with FACS Diva software (BD Biosciences).

Measurement of IgG and CTL responses

The IgG level in each of the 31 peptide candidates was measured using the Luminex system (Luminex, Austin, TX, USA), as previously reported.8,9 The IgG levels were obtained as fluorescence intensity units (FIU). If the level of peptide-specific IgG to at least one of the vaccinated peptides in the post-vaccination plasma was more than twice that in the pre-vaccination plasma, the response was considered augmented. For the analysis of IgG response to the peptides, FIU values were converted to IgG scores, which were calculated by the formula

graphic file with name cas0105-1229-m1.jpg

The CTL responses were evaluated by IFN-γ ELISPOT assay as previously described.8,9 Antigen-specific T-cell responses were evaluated by the difference between the number of spots produced in response to each corresponding peptide and that produced in response to the control HIV peptide; a difference of more than 30 spots per 105 PBMCs with statistical significance (P < 0.05) was considered positive or detectable and the subtracted spot numbers are shown. In negative cases, spot numbers are shown as 0. If a post-vaccination value was more than twice the pre-vaccination value with statistical significance (P < 0.05 by t-test), the response was considered augmented. If a pre-vaccination value was 0, more than 30 post-vaccination values were considered augmented responses. The CTL response data will be published in another manuscript (T. Yamada et al., in preparation). Previously published data (n = 21)9 were also used for the analyses.

Statistical analysis

The survival curves were examined by the Kaplan–Meier method. Differences between the pre- and post-vaccination groups for each variable were compared by the log-rank test for the analysis of the survival curves. Pearson's χ2 test and the anova were used to analyze T-cell responses specific to the vaccinated peptides and IgG responses to the vaccine peptides, respectively. A P-values <0.05 were considered significant. All statistical analyses were performed using JMP version10 software (SAS Institute, Cary, NC, USA).

Results

Patient characteristics

Seventy-eight patients with advanced (stages IIIb and V) or recurrent NSCLC receiving PPV treatment were included in this study. Table1 shows their characteristics. By the start of PPV treatment, 73 of the 78 patients had failed at least one regimen of chemotherapy: 16, 22, 11, and 24 patients had, respectively, failed 1, 2, 3, or 4–12 regimens. The remaining five patients were naïve to any chemotherapy regimens before PPV treatment.

Table 1.

Characteristics of 78 advanced non-small cell lung cancer (NSCLC) patients treated with personalized peptide vaccination

Parameter n Median (range)
Overall Survival (days) 78 639 (76–1497)
Age (years) 63 (35–84)
Gender
 Male 38
 Female 40
Stage
 IIIb 8
 IV 36
Recurrence 34
Histology
 Adeno 63
 Adenosquamous 2
 Squamous 11
 LCC 1
 Pleomorphic 1
Pre-vaccination regimen No. 3 (0–12)
Open in a new tab

Expression of immune checkpoint molecules on peripheral blood lymphocytes

Expression of two co-inhibitory molecules, CTLA-4 (CD152) and PD-1 (CD279), and one co-stimulatory molecule, 4-1BB (CD137) on lymphocytes of the patients' PBMCs were examined. Although these three molecules were expressed on PHA-activated lymphocytes, only PD-1 was detectable on non-stimulated lymphocytes of the majority of patients and the other two molecules were rarely expressed on the peripheral blood lymphocytes (data not shown). Therefore, further analyses focused on the expression of PD-1 on patients' lymphocytes. Figure1 shows representative staining patterns of PD-1 on CD4+ and CD8+ T-cell subsets as well as total lymphocytes.

Figure 1.

Figure 1

Open in a new tab

Representative staining patterns of PD-1 on lymphocytes, CD4+ T-cells, and CD8+ T-cells of two patients, FLU-066 (a) and FLU-018 (b), with advanced non-small cell lung cancer (NSCLC). The baseline for the PD-1 staining was determined using isotype-matched control. The left panels show histograms of lymphocyte gated cells.

PD-1 expression and prognosis

We examined PD-1 expression in T-cells of PBMCs obtained from patients before and after one cycle of six or eight vaccination doses. The median relative contents of PD-1+ CD4+ T-cells against total lymphocytes were 7.35% (range, 2.4–20.1%) and 7.6% (3.4–26.2%) at pre- and post-vaccination; those of PD-1+CD8+ T-cells against total lymphocytes were 4.4% (1.4–14.3%) and 4.25% (1.6–19.0); and those of PD-1+ lymphocytes against total lymphocytes were 13.85% (6.6–29.2%) and 13.7% (6.0–42.0%).

Subsequently we analyzed the correlation between the relative contents of PD-1+ cells and overall survival (OS) by a Kaplan–Meier plot (Fig.2). “Median” of % PD-1+ cells were used for the definition of “high” and “low” contents of PD-1+ cells. The relative contents of PD1+CD4+ T-cells against total lymphocytes of pre-vaccination samples correlated to OS with high significance (P < 0.0001 by the log-rank test, hazard ratio [HR] = 0.229, 95% confidence interval [CI]: 0.097–0.483) (panel a). Namely, the high content of the PD-1+CD4+ T-cell group expressed longer OS than the low content of the PD-1+CD4+ T-cell group. The median OS time (MST) value of the low PD-1+CD4+ group was 411 days; that of the high-PD-1+CD4+ group did not reach MST. The percentages of PD-1+CD8+ T-cells against total lymphocytes of pre-vaccination samples did not correlate with OS (panel b). A similar tendency was observed in the post-vaccination samples (see panels c, d), i.e., the PD-1+CD4+ high-content group correlated with OS (P = 0.0014, HR = 0.297, 95% CI: 0.126-0.627; the MST values of the high and low groups were not reached and 411 days, respectively). It is noteworthy that the relative contents of CD4+ or CD8+ T-cells against total lymphocytes of both pre- and post-vaccination samples expressed no correlation with OS (data not shown). We further analyzed the correlation between the differences in the pre- and post-vaccination contents of PD-1+ T-cell subsets and OS. As shown in Figure2(f), the decrease in PD-1+CD8+ T-cells after one cycle of vaccination correlated to longer OS (P = 0.0327, HR = 0.482, 95% CI: 0.238–0.947; the MST values of the decreased and non-decreased groups were 1286 and 423 days), and no correlation was observed in PD-1+CD4+ T-cell contents (panel e).

Figure 2.

Figure 2

Open in a new tab

Correlation between the relative contents of PD-1+ cells and overall survival (OS) was analyzed by a Kaplan–Meier plot. PD-1 expression on CD4+ (a, c) and CD8+ (b, d) T-cells of the blood samples obtained from the patients at pre-vaccination (a, b), or post one cycle-vaccination (c, d) were analyzed. Kaplan–Meier curve for decrease in the frequency of PD-1+CD4+ (e) or PD-1+CD8+ (f) T-cells after one cycle vaccination are also shown. NR, not reached.

The pre- and post-vaccination contents of PD-1+CD4+ T-cells were significantly correlated (P < 0.001). In contrast, there was no correlation between the pre-vaccination contents of PD-1+CD4+ T-cells and the difference of PD1+CD8+ T-cells between pre- and post-vaccination, or between the post-vaccination contents of PD-1+CD4+ T-cells and the difference in PD1+ CD8+ T-cells (data not shown). Univariate analysis indicated that the high-contents of pre- and post-vaccination PD-1+CD4+ T-cells were correlated to longer OS, as was the decrease in PD1+CD8+ T-cells. Multivariate analysis showed that the post-vaccination contents of PD-1+CD4+ T-cells and the decrease in PD1+CD8+ T-cells were independent factors for longer OS, and the combination of these two factors is a stronger prognostic factor than either factor alone (Table S1).

Neither the high- and low-content nor the decreased and non-decreased groups differed significantly in any of the patient's background factors, such as age, gender, stages, and histology, except for OS (data not shown).

PD-1 expression and CTL response

We analyzed the relationships between CTL responses to the vaccinated peptides and the PD-1+CD4+ T-cell contents at pre- and post-vaccination, as well as the relationships between the CTL responses and the difference in PD-1+CD8+ T-cell contents. Forty-nine patients were included in this analysis, since no sufficient blood samples from pre- and post-vaccination were available from the remaining patients. A response was considered augmented if the IFN-γ ELISPOT-cell numbers more than doubled after the vaccination cycle against at least one vaccinated peptide. The percentages of CTL-response-augmented cases among the 49 cases in the PD-1+CD4+ T-cell high- and low-content groups were 47.6% (10/21) and 47.0% (13/28), respectively, at pre-vaccination; 47.4% (9/19) and 46.7% (14/30) at post-vaccination; and 50.0% (12/24) and 44.0% (11/25) in the decreased and non-decreased groups of PD-1+CD8+ T-cell contents after the cycle (Fig.3). These groups showed no differences in CTL responses for any parameter.

Figure 3.

Figure 3

Open in a new tab

Correlation between the relative contents of PD-1+ T-cell subsets and CTL responses. The CTL responses were evaluated by IFN-γ ELISPOT assay. The definition of the augmented CTL responses is described in Materials and Methods. The P-values were calculated by the Pearson's χ2 test.

PD-1 expression and IgG response

We analyzed the relationships between IgG responses to the vaccinated peptides and the PD-1+CD4+ T-cell contents at pre- and post-vaccination, as well as the relationship between the IgG responses and the difference in PD-1+CD8+ T-cell contents. For each parameter, changes in the sums of IgG scores after the cycle were compared between the groups. As shown in Figure4(a), IgG responses to the vaccinated peptides in the PD-1+CD4+ high-content group were significantly higher than those in the PD-1+CD4+ low-content group both before and after vaccination (P = 0.0267 and P = 0.0308, respectively). Analysis of the IgG subclass in the representative cases indicated that IgG1, IgG2, and IgG3 were equally dominant in both the pre- and post-vaccination samples from the PD-1+ T-cell high- and low-content groups (data not shown).

Figure 4.

Figure 4

Open in a new tab

(a) The correlation between the relative contents of PD-1+ T-cell subsets and the IgG response to the peptides used for vaccination was analyzed. Changes in the sums of IgG scores after one cycle of vaccination were compared between the two groups for each parameter. (b) The number of non-vaccinated peptides with augmented IgG responses after one cycle of vaccination was compared between the two groups for each parameter. (c) Changes in sums of scores of IgG against non-vaccinated peptides after one cycle of vaccination were compared between two groups for each parameter. P-values were calculated by anova.

We also measured IgG responses to the peptides that were not used for the vaccination, designated as non-vaccinated peptides, to examine how vaccination spread the epitope, and we analyzed the correlation between the groups for each parameter. An IgG response was considered augmented if the IgG value against the peptide was more than doubled after the cycle. The number of peptides corresponding to the augmented IgG responses was compared between the two groups for each parameter. As shown in Figure4(b), there were significantly more peptides in the PD-1+CD4+ high-content group than in the PD-1+CD4+ low-content group at post-vaccination (P = 0.0079). Changes in the sums of IgG scores against the nonvaccinated peptides after the cycle were also compared between the groups for each parameter (Fig.4c). The changes in the PD-1+CD4+ high-content group were also significantly higher than those in the PD-1+CD4+ low-content group at post-vaccination (P = 0.0016).

Effector memory T-cells are enriched in PD-1+ T-cells

We further analyzed the cell surface expression of CD45RA and CCR7 on PD-1+ T-cell subsets of NSCLC patients (n = 18). Representative results are shown in Figure5. The majority of PD-1+CD4+ T-cells expressed the CD45RA−CCR7− effector-memory phenotype (median = 75.6%, range 57.2–91.3%), and the median frequencies of CD45RA−CCR7+ central memory and CD45RA+CCR7+-naïve phenotype cells were 10.4% (5.4–21.6%) and 7.55% (0.2–19.5%), respectively. In contrast, the median frequency of CD45RA−CCR7− effector-memory and CD45RA+CCR7+-naïve phenotype cells were respectively 37.7% (19.1–78.4%) and 39.95% (4.5–61.7%) in PD-1−CD4+ T-cells. Similarly, in CD8+ T-cells the effector-memory phenotype of cells was dominant (median = 83.85%, 47.9–92.6%) in PD-1+ cells. Similar results were also obtained from PBMCs of healthy donors (data not shown). The enrichment of effector-memory T-cells in PD-1+ T-cells in PBMCs was consistent with previous reports of healthy donors and HCV/HIV co-infected patients.23,24

Figure 5.

Figure 5

Open in a new tab

Cell surface expression of CD45RA and CCR7 on PD-1 T-cell subsets of non-small cell lung cancer (NSCLC) patients were analyzed. Representative data are shown.

Discussion

For the development of new treatment modalities, the co-development of new biomarkers is important. Particularly for cancer vaccines, it is crucial to identify appropriate biomarkers to predict overall survival, since only some patients will show clinical benefit. Our previous clinical studies of PPV indicated that several biomarkers were significantly correlated with the OS.8,9,25,26 In the case of NSCLC, a high CRP level at pre-vaccination and a low frequency of CD26+ T-cells in the peripheral blood after one vaccination cycle were significant biomarkers of unfavorable OS.9 However, most of these biomarkers are prognostic but not predictive. The MST of a phase II study of PPV in 44 patients with refractory NSCLC, including 4 stage IIIb, 22 stage IV, and 15 recurrent, was 304 days, with a 1-year survival rate of 42%.9 These results are equal or superior to those of previous reports with MSTs of 6–8 months.9 If appropriate predictive biomarkers are identified, the clinical efficacy of PPV might be improved.

We have demonstrated in this study that relatively high contents of PD-1+CD4+ T-cells against total lymphocytes of blood samples obtained before and after a vaccination cycle and a decrease in PD-1+CD8+ T-cells after a vaccination cycle were correlated with longer OS. Among them, high contents of post-vaccination PD-1+CD4+ T-cells and a decrease in PD-1+CD8+ T-cells were correlated to high contents of CD26+ T-cells, in contrast, no significant correlation was observed between the CRP levels and the contests of PD-1+ T-cell subsets (data not shown). A similar correlation, between a high frequency of PD-1+CD4+ T-cells in pre-treatment blood samples and prolonged OS, was reported in a clinical study of prostate GVAX plus ipilimumab (anti-CTLA-4) in patients with metastatic castration-resistant prostate cancer.27 Expression of PD-1 on peripheral blood T-cells of patients with malignant tumor has been reported.16,20–22 Most of the previous reports suggested that PD-1 is a marker of exhausted T-cells, and some of these reports described the dysfunction of tumor-infiltrating PD-1+CD8+ T-cells. However, the functional difference between PD-1+ and PD-1− T-cells in the peripheral blood has not been clarified satisfactorily. Follicular helper T-cells (Tfh) have recently been identified and those surface phenotype is CXCR5+PD-1highCD4+.28 Only a small part of PD-1+CD4+ cells found in this study expressed CXCR5, suggesting these cells are different from Tfh (Fig. S1). If PD-1 is a marker of exhausted T-cells in the peripheral blood, it is hard to explain why the increased frequency of PD-1+CD4+ T-cells in the peripheral blood correlated with better prognosis in patients with NSCLC. Duraiswamy et al.23 analyzed the phenotype, function, and gene expression of PD-1+CD8+ T-cells and concluded that most PD-1highCD8+ T-cells in healthy adult humans are effector memory cells rather than exhausted cells. In the present study, we analyzed the phenotypes of PD-1+ T-cells in the peripheral blood and found that the majority of PD-1+CD4+ and PD-1+CD8+ T-cells expressed the CD45RA−CCR7− effector-memory phenotype. Effector-memory T-cells are home to peripheral tissues and can rapidly produce effector cytokines such as IFN-γ upon antigenic stimulation.29 Therefore, PD-1+ T-cells observed in the peripheral blood of patients with NSCLC may not be exhausted or tolerant T-cells. Our preliminary study using anti-PD-L1 blocking antibody also supported this possibility. Namely, anti-PD-L1 antibody augmented the anti-CD3/CD28-induced IFN-γ response of PD-1+ tumor-infiltrated T-cells (TILs) of NSCLC patients, suggesting that the activation of PD-1+ TILs is suppressed by the PD-1/PD-L1 pathway. In contrast, the addition of anti-PD-L1 was less effective in such a stimulation induced IFN-γ response of PD-1+ peripheral blood T-cells from the same donor, although PD-L1 was similarly expressed in both TILs and PBMCs (Fig. S2). Another explanation of the correlation between an increased frequency of PD-1+CD4+ T-cells in the peripheral blood and better prognosis is the different distribution of PD-L1 in the peripheral lymph nodes and cancer tissues. It is well known that PD-L1 expression is upregulated in most cancer tissues. It is unknown whether PD-1 on CD4 helper T-cells supplies a negative signal at lymph nodes in which PD-L1 is not upregulated, and PD-1+ regulatory T-cells may suppress its function at tumor sites where PD-L1 is upregulated. If PD-1+ T-cells function as effector memory T-cells, it is hard to explain why the decrease in PD-1+CD8+ T-cells after vaccination correlates to longer OS. One possibility is the vaccination regimen used in this study induced the efficient recruitment of PD-1+CD8+ T-cells into the tumor region, resulting in a decrease in the cell population in peripheral blood. Indeed, increased infiltration of CD8+ T-cells into the tumor region had been confirmed in vaccinated patients with prostate cancer.30 Further precise studies are needed to clarify these issues.

We showed that IgG response correlated to high content of PD-1+CD4+ T-cells, which in turn correlated to good prognosis, and that CTL response did not correlate to any PD-1+ T-cell parameters. However, CTL response rather than IgG response was the good marker of OS (T. Yamada et al., in preparation). Dissociation between the CTL-response and PD-1+CD8+ T-cell contents might be due to the low contents of PD-1+ cells in CD8+ T-cells, in which both the PD-1+ and PD-1− cells have a potential of CTL. The present study included patients treated with vaccine monotherapy or a combination of vaccination with chemotherapy or molecular targeting therapy; these therapies might affect the CTL response as well as PD-1 expression and prognosis. To clarify these issues, further study using segment analysis with large numbers of patients is needed.

Many clinical trials of anti-immune checkpoint antibodies and antagonists are now under way.31,32 In the case of PD-1, clinical studies of several anti-PD-1 antibodies were conducted in patients with various malignant tumors including NSCLC.33–38 All of those studies found that these anti-PD-1 antibodies were tolerable and showed promising clinical benefits. The combination of cancer vaccines and immune checkpoint blockades will become a new trend in cancer immunotherapy.31,32 PD-1 as well as other checkpoint molecules on peripheral blood T-cells become target molecules in combination therapy. Thus the expression of PD-1 on T-cells may provide different predictions in combination therapy.

In conclusion, we found that the relatively high contents of PD-1+CD4+ T-cells in the peripheral blood, as well as the decrease inPD-1+CD8+ T-cells after vaccination, were correlated with longer OS. These results suggest that PD-1 expression in peripheral blood T-cell subsets will become a new prognostic marker for NSCLC patients treated with personalized peptide vaccination.

Acknowledgments

This study was supported in part by the grants from the Private University Strategic Research Foundation Support Program of the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT), the Regional Innovation Cluster Program of MEXT, and the Sendai Kousei Hospital.

Disclosure Statement

Akira Yamada is a board member of the Green Peptide Co. (Kurume, Japan).

Supporting Information

Fig. S1. CXCR5+PD-1+CD4+ T-cells are minor population and did not increase in PD-1+CD4+ high case.

cas0105-1229-sd1.tif (155.7KB, tif)

Fig. S2. (a) PD-L1 expression on PBLs and TILs from the same patient with NSCLC. (b) Anti-PD-L1 antibody augmented the CD3/CD28-bead-induced IFN-γ response of TILs, but not of PBLs.

cas0105-1229-sd2.tif (430.4KB, tif)

Table S1. Univariate and multivariate analysis of PD-1+ T-cell contents with OS.

cas0105-1229-sd3.docx (19.5KB, docx)

References

  1. GLOBOCAN. 2012. Estimated cancer incidence, mortality and prevalence worldwide in 2012. [Cited 19 Mar 2014.] Available from URL: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
  2. Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer. 2005;117:294–9. doi: 10.1002/ijc.21183. [DOI] [PubMed] [Google Scholar]
  3. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF. Management of non-small-cell lung cancer: recent developments. Lancet. 2013;382:709–19. doi: 10.1016/S0140-6736(13)61502-0. [DOI] [PubMed] [Google Scholar]
  4. Forde PM, Ettinger DS. Targeted therapy for non-small-cell lung cancer: past, present and future. Expert Rev Anticancer Ther. 2013;13:745–58. doi: 10.1586/era.13.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F. ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev. 2014;40:300–6. doi: 10.1016/j.ctrv.2013.07.002. [DOI] [PubMed] [Google Scholar]
  6. Yamada A, Sasada T, Noguchi M, Itoh K. Next-generation peptide vaccines for advanced cancer. Cancer Sci. 2013;104:15–21. doi: 10.1111/cas.12050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Sasada T, Yamada A, Noguchi M, Itoh K. Personalized peptide vaccine for treatment of advanced cancer. Curr Med Chem. 2014;21:2332–45. doi: 10.2174/0929867321666140205132936. [DOI] [PubMed] [Google Scholar]
  8. Terazaki Y, Yoshiyama K, Matsueda S, et al. Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer. Cancer Sci. 2012;103:638–44. doi: 10.1111/j.1349-7006.2012.02202.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Yoshiyama K, Terazaki Y, Matsueda S, et al. Personalized peptide vaccination in patients with refractory non-small cell lung cancer. Int J Oncol. 2012;40:1492–500. doi: 10.3892/ijo.2012.1351. [DOI] [PubMed] [Google Scholar]
  10. Kamphorst AO, Ahmed R. Manipulating the PD-1 pathway to improve immunity. Curr Opin Immunol. 2013;25:381–8. doi: 10.1016/j.coi.2013.03.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24:207–12. doi: 10.1016/j.coi.2011.12.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004;10:5094–100. doi: 10.1158/1078-0432.CCR-04-0428. [DOI] [PubMed] [Google Scholar]
  13. Thompson RH, Dong H, Lohse CM, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007;13:1757–61. doi: 10.1158/1078-0432.CCR-06-2599. [DOI] [PubMed] [Google Scholar]
  14. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T-cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci USA. 2010;107:7875–80. doi: 10.1073/pnas.1003345107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hsu MC, Hsiao JR, Chang KC, et al. Increase of programmed death-1-expressing intratumoral CD8 T-cells predicts a poor prognosis for nasopharyngeal carcinoma. Mod Pathol. 2010;23:1393–403. doi: 10.1038/modpathol.2010.130. [DOI] [PubMed] [Google Scholar]
  16. Zhang Y, Huang S, Gong D, Qin Y, Shen Q. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol. 2010;7:389–95. doi: 10.1038/cmi.2010.28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D, Gillanders WE. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2013;139:667–76. doi: 10.1007/s10549-013-2581-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Sun S, Fei X, Mao Y, et al. PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients. Cancer Immunol Immunother. 2014;63:395–406. doi: 10.1007/s00262-014-1519-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Webb JR, Milne K, Watson P, Deleeuw RJ, Nelson BH. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res. 2014;20:434–44. doi: 10.1158/1078-0432.CCR-13-1877. [DOI] [PubMed] [Google Scholar]
  20. Malaspina TS, Gasparoto TH, Costa MR, et al. Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma. Cancer Immunol Immunother. 2011;60:965–74. doi: 10.1007/s00262-011-1007-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Baruah P, Lee M, Odutoye T, et al. Decreased levels of alternative co-stimulatory receptors OX40 and 4-1BB characterise T-cells from head and neck cancer patients. Immunobiology. 2012;217:669–75. doi: 10.1016/j.imbio.2011.11.005. [DOI] [PubMed] [Google Scholar]
  22. Krönig H, Julia Falchner K, Odendahl M, et al. PD-1 expression on Melan-A-reactive T-cells increases during progression to metastatic disease. Int J Cancer. 2012;130:2327–36. doi: 10.1002/ijc.26272. [DOI] [PubMed] [Google Scholar]
  23. Duraiswamy J, Ibegbu CC, Masopust D, et al. Phenotype, function, and gene expression profiles of programmed death-1(hi) CD8 T-cells in healthy human adults. J Immunol. 2011;186:4200–12. doi: 10.4049/jimmunol.1001783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Saha B, Choudhary MC, Sarin SK. Expression of inhibitory markers is increased on effector memory T-cells during hepatitis C virus/HIV coinfection as compared to hepatitis C virus or HIV monoinfection. AIDS. 2013;27:2191–200. doi: 10.1097/QAD.0b013e32836285e4. [DOI] [PubMed] [Google Scholar]
  25. Yutani S, Komatsu N, Yoshitomi M, et al. A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients. Oncol Rep. 2013;30:1094–100. doi: 10.3892/or.2013.2556. [DOI] [PubMed] [Google Scholar]
  26. Yutani S, Komatsu N, Matsueda S, et al. Juzentaihoto failed to augment antigen-specific immunity but prevented deterioration of patients' conditions in advanced pancreatic cancer under personalized peptide vaccine. Evid Based Complement Alternat Med. 2013;2013:981717. doi: 10.1155/2013/981717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Santegoets SJ, Stam AG, Lougheed SM, et al. T-cell profiling reveals high CD4+CTLA-4 + T-cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol Immunother. 2013;62:245–56. doi: 10.1007/s00262-012-1330-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Tangye SG, Ma CS, Brink R, Deenick EK. The good, the bad and the ugly – TFH cells in human health and disease. Nat Rev Immunol. 2013;13:412–26. doi: 10.1038/nri3447. [DOI] [PubMed] [Google Scholar]
  29. Lanzavecchia A, Sallusto F. Understanding the generation and function of memory T-cell subsets. Curr Opin Immunol. 2005;17:326–32. doi: 10.1016/j.coi.2005.04.010. [DOI] [PubMed] [Google Scholar]
  30. Noguchi M, Yao A, Harada M, et al. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer. Prostate. 2007;67:933–42. doi: 10.1002/pros.20572. [DOI] [PubMed] [Google Scholar]
  31. Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res. 2013;19:997–1008. doi: 10.1158/1078-0432.CCR-12-2214. [DOI] [PubMed] [Google Scholar]
  32. Brahmer JR. Harnessing the immune system for the treatment of non-small-cell lung cancer. J Clin Oncol. 2013;31:1021–8. doi: 10.1200/JCO.2012.45.8703. [DOI] [PubMed] [Google Scholar]
  33. McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med. 2013;2:662–73. doi: 10.1002/cam4.106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167–75. doi: 10.1200/JCO.2009.26.7609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54. doi: 10.1056/NEJMoa1200690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Armand P, Nagler A, Weller EA, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol. 2013;31:4199–206. doi: 10.1200/JCO.2012.48.3685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Lipson EJ, Sharfman WH, Drake CG, et al. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS ONE. 2013;8:e63818. doi: 10.1371/journal.pone.0063818. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134–44. doi: 10.1056/NEJMoa1305133. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Fig. S1. CXCR5+PD-1+CD4+ T-cells are minor population and did not increase in PD-1+CD4+ high case.

cas0105-1229-sd1.tif (155.7KB, tif)

Fig. S2. (a) PD-L1 expression on PBLs and TILs from the same patient with NSCLC. (b) Anti-PD-L1 antibody augmented the CD3/CD28-bead-induced IFN-γ response of TILs, but not of PBLs.

cas0105-1229-sd2.tif (430.4KB, tif)

Table S1. Univariate and multivariate analysis of PD-1+ T-cell contents with OS.

cas0105-1229-sd3.docx (19.5KB, docx)

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES